Pittenger & Anderson Inc. Boosts Stock Holdings in Danaher Co. (NYSE:DHR)

Pittenger & Anderson Inc. lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 3.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,823 shares of the conglomerate’s stock after buying an additional 2,116 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Danaher were worth $18,856,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Sentry Investment Management LLC boosted its stake in Danaher by 65.6% in the 3rd quarter. Sentry Investment Management LLC now owns 3,086 shares of the conglomerate’s stock worth $858,000 after purchasing an additional 1,223 shares during the period. United Advisor Group LLC purchased a new stake in shares of Danaher in the third quarter worth about $230,000. ASB Consultores LLC boosted its position in shares of Danaher by 6.8% in the third quarter. ASB Consultores LLC now owns 3,237 shares of the conglomerate’s stock valued at $900,000 after acquiring an additional 206 shares during the period. James J. Burns & Company LLC grew its stake in Danaher by 6.3% during the third quarter. James J. Burns & Company LLC now owns 1,796 shares of the conglomerate’s stock valued at $499,000 after acquiring an additional 106 shares in the last quarter. Finally, Greenwood Capital Associates LLC increased its holdings in Danaher by 19.9% during the 3rd quarter. Greenwood Capital Associates LLC now owns 33,526 shares of the conglomerate’s stock worth $9,321,000 after acquiring an additional 5,559 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Trading Down 0.2 %

NYSE:DHR opened at $247.18 on Tuesday. The firm has a market capitalization of $178.53 billion, a P/E ratio of 47.17, a P/E/G ratio of 4.55 and a beta of 0.85. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a fifty day moving average of $266.53 and a 200 day moving average of $260.74. Danaher Co. has a 52 week low of $192.35 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.02 earnings per share. On average, research analysts predict that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 20.61%.

Insider Activity

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 10.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DHR. Raymond James reduced their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Robert W. Baird decreased their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Evercore ISI lifted their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. The Goldman Sachs Group upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Stifel Nicolaus boosted their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.